Guizhou Yibai Pharmaceutical Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Guizhou Yibai Pharmaceutical Co., Ltd. carries a market capitalization of 2.61B, placing it among publicly traded companies globally. Its enterprise value stands at 3.41B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.61B |
| Enterprise Value | 3.41B |
Share Statistics
Guizhou Yibai Pharmaceutical Co., Ltd. currently has 791.93M shares outstanding.
| Shares Outstanding | 791.93M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.51, and the price-to-book ratio stands at 1.97.
| PE Ratio | N/A |
| PS Ratio | 1.51 |
| PB Ratio | 1.97 |
| P/TBV Ratio | 1.41 |
| P/FCF Ratio | 48.76 |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 1.71 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 41.35 |
Financial Position
Guizhou Yibai Pharmaceutical Co., Ltd. maintains a current ratio of 1.80, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 38.08, indicating elevated leverage, while an interest coverage ratio of -6.70 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.80 |
| Quick Ratio | 0.70 |
| Debt / Equity | 38.08 |
| Debt / EBITDA | -7.17 |
| Interest Coverage | -6.70 |
Financial Efficiency
| Return on Equity (ROE) | -14.05 |
| Return on Assets (ROA) | -5.45 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.33 |
Taxes
| Income Tax | 3.72M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Guizhou Yibai Pharmaceutical Co., Ltd.'s stock has declined approximately -18.56436% over the past 52 weeks. The 50-day moving average sits at 3.61, while the 200-day moving average is 4.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | -18.56436% |
| 50-Day Moving Average | 3.61 |
| 200-Day Moving Average | 4.03 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Guizhou Yibai Pharmaceutical Co., Ltd. generated 2.00B in revenue and converted that into -230.62M in net income, yielding earnings per share of -0.31. EBITDA reached -137.31M, while operating income came in at -137.31M.
| Revenue | 2.00B |
| Gross Profit | 1.22B |
| Operating Income | -137.31M |
| Pretax Income | -242.34M |
| Net Income | -230.62M |
| EBITDA | -137.31M |
| EBIT | -137.31M |
| Earnings Per Share (EPS) | -0.31 |
Balance Sheet
Guizhou Yibai Pharmaceutical Co., Ltd. holds 695.15M in cash and equivalents against 983.89M in total debt, resulting in a net debt position of 65.75M. Total book value stands at 1.53B, with working capital of 787.75M providing operational flexibility.
| Cash & Cash Equivalents | 695.15M |
| Total Debt | 983.89M |
| Net Debt | 65.75M |
| Equity (Book Value) | 1.53B |
| Book Value Per Share | 1.95 |
| Working Capital | 787.75M |
Cash Flow
After subtracting -61.76M in capital expenditures, free cash flow totaled -61.76M - equivalent to -0.08 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -61.76M |
| Free Cash Flow | -61.76M |
| FCF Per Share | -0.08 |
Margins
Guizhou Yibai Pharmaceutical Co., Ltd. operates with a gross margin of 60.90, reflecting its pricing power and cost economics. The operating margin of -6.87 and net profit margin of -11.54 provide insight into operational efficiency.
| Gross Margin | 60.90 |
| Operating Margin | -6.87 |
| Pretax Margin | -12.12 |
| Profit Margin | -11.54 |
| EBITDA Margin | -6.87 |
Dividends & Yields
The company's payout ratio of -11.78 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.04 |
| Dividend Yield | N/A |
| Payout Ratio | -11.78 |
| Shareholder Yield | 0.45 |
| FCF Yield | 2.05 |
Stock Splits
Guizhou Yibai Pharmaceutical Co., Ltd.'s most recent stock split took place on July 16, 2015 with a 1:2 split ratio.
| Last Split Date | 7/16/2015 |
| Split Ratio | 1:2 |
Scores
Guizhou Yibai Pharmaceutical Co., Ltd. posts an Altman Z-Score of 2.21, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.21 |